Novocure Ltd

NASDAQ NVCR

Data sourced from

and

Daily

Download Data

Novocure Ltd Enterprise Value (EV) on June 03, 2024: USD 2.35 B

Novocure Ltd Enterprise Value (EV) is USD 2.35 B on June 03, 2024, a -72.05% change year over year. Enterprise Value is a measure of a company's total value, including both its equity and debt. It represents the theoretical takeover price of a company and is often used in valuation methods. Enterprise value is calculated as the sum of a company's market capitalization, total debt, and subtracting its cash and short-term investments.

Novocure Ltd 52-week high Enterprise Value (EV) is USD 8.39 B on June 05, 2023, which is 257.77% above the current Enterprise Value (EV).
Novocure Ltd 52-week low Enterprise Value (EV) is USD 912.61 M on November 10, 2023, which is -61.10% below the current Enterprise Value (EV).
Novocure Ltd average Enterprise Value (EV) for the last 52 weeks is USD 1.93 B.

NASDAQ: NVCR

Novocure Ltd

CEO	Mr. William F. Doyle
IPO Date	Oct. 2, 2015
Location	Jersey
Headquarters	No. 4 The Forum, Saint Helier, Jersey, JE2 4UF
Employees	1,453
Sector	Healthcare
Industry	Medical devices

Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Key trends